Skip to main content

Horizon Therapeutics — Deal History & Benchmarks

Total Deals
2
Across 2 therapeutic areas
Total Deal Value
$30.9B
Cumulative transaction value
Most Active Year
2023
1 deal closed
Primary TA
Immunology & Autoimmune
50% of deal activity

Market Analysis

Horizon Therapeutics has been involved in 2 transactions totaling $30.9B across Immunology & Autoimmune, Rare Disease. As both a licensor and licensee, they have demonstrated an active acquisition strategy.

Key transactions include Amgen ($27.8B, 2023), Viela Bio ($3.0B, 2020).

Their deal activity is concentrated in Immunology & Autoimmune (50%) with Monoclonal Antibody assets representing their most common deal type.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How many deals has Horizon Therapeutics done?
Horizon Therapeutics has completed 2 verified transactions tracked in our database, spanning from 2020 to 2023. These deals have a combined value of $30.9B.
What is Horizon Therapeutics's typical deal structure?
Based on 2 deals, Horizon Therapeutics's transactions show a median upfront payment of $3.0B. Their most common deal type is acquisition, reflecting an active acquisition strategy.
What therapeutic areas does Horizon Therapeutics focus on?
Horizon Therapeutics is primarily active in Immunology & Autoimmune (50%), Rare Disease (50%).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough